Home - Melanoma Research Alliance

Challenge Accepted

This was a year like no other.

COVID-19 presented new challenges that required new ways of thinking. At MRA, confronting challenges is part of our DNA. We never stop challenging ourselves, no matter the odds or obstacles, in pursuit of conquering melanoma and saving lives.

Read our 2020 - 2021 Annual Report where you can find examples of our work, latest newest grantees, audited financials, & more.

Read the Annual Report

New Melanoma Research Funding

MRA is pleased to announce a Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.

This award cycle is anticipated to support at least $11.3 million in new funding.

Learn More

Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma

After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.

Craig Finds Meaning in His Melanoma Diagnosis in the COVID-19 Era

“I believe there is a reason that I’m going through this. If I can help prevent someone else’s melanoma, or make their journey easier, or help advance research – that’d be worth it,” says Craig. “I feel honored to be part of the melanoma community. It’s a powerful community – and I feel obligated to do something in support of it.”

New Immunotherapy Drugs Targeting LAG-3 Show Great Promise

Researchers presented a series of highly encouraging clinical trial results at the recent American Society for Clinical Oncology (ASCO) annual meeting that suggest that new drugs targeting the protein LAG-3 – developed by BMS and Regeneron – may be an important addition to the current treatment arsenal.